Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.
The Food and Drug Administration (FDA) has granted dual 510(k) clearances for the pocket-sized Kardia 12L electrocardiography (ECG) system and KAI 12L artificial intelligence (AI) technology, which may bolster the detection of life-threating cardiac conditions with a reduced leadset.
Trained on more than 175 million ECGs, the deep neural network algorithms with KAI 12L may facilitate the diagnosis of 35 cardiac determinations, including common forms of cardiac ischemia and acute myocardial infarction, according to AliveCor, the developer of the technology.
Dual FDA clearances for the pocket-sized Kardia 12L ECG System (shown above) and the KAI 12L AI technology, trained on more than 175 million ECGs, may bolster the detection of cardiac conditions and facilitate use of the technology in resource-challenged health-care facilities, according to AliveCor, the developer of the modalities. (Photo courtesy of AliveCor.)
"Not only is it the first FDA-cleared AI that can detect a heart attack on a reduced leadset, but it also returns determinations for our broadest range of conditions yet," said Priya Abani, the CEO of AliveCor. "Paired with our pocket-sized Kardia 12L ECG System, this offering is poised to disrupt traditional care pathways and represents a leap forward in cardiac care."
In comparison to standard 12-lead ECG devices, the pocket-sized Kardia 12L ECG system enables clinicians to capture eight quality diagnostic bandwidth leads with five electrodes and a single cable. AliveCor added that the portability of the battery-operated, 0.3-lb. device may expand access to the technology for a variety of health-care facilities including resource-challenged centers or rural medical facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.